Joint Commercial Committee Sample Clauses

Joint Commercial Committee. Within ten (10) days of the Effective Date, the Parties will establish a Joint Commercial Committee (the “JCC”) comprised of at least three (3) members representing each Party, all of whom shall have appropriate expertise and seniority to enable them to make decisions on behalf of the Parties with respect to the issues falling within the jurisdiction of the JCC. The JCC will follow the organizational and meeting procedures set forth in Section 6.4.
Sample 1
AutoNDA by SimpleDocs
Joint Commercial Committee. (1) On or within thirty (30) days after the Effective Date, the Parties shall establish and appoint members to the Joint Commercial Committee ("JCC" or "Committee"), which shall consist of two (2) members from each Party who shall meet in-person, by telephone or by video-conference at least quarterly to review the overall progress as well as the Commercial Plans (as defined below). The JCC will have various responsibilities and all decisions and recommendations by the Committee shall be by unanimous agreement of the respective representatives of XXX and CRTX, and, in the event of a tie, the matter shall be referred for resolution by the Chief Executive Officer of each Party. If the Chief Executive Officers from the Parties cannot resolve a given dispute within thirty (30) days, the parties shall submit the dispute to mediation pursuant to Section 13.6 of this Agreement.
Sample 1
Joint Commercial Committee. Establishment and Composition • The JCC will be formed upon exercise of PTI’s Co-Promotion Option.
Sample 1
Joint Commercial Committee. Subject to the terms of this Agreement, including Section 3.4.5, the JCC shall: (a) review and approve a strategy throughout the Territory for the Commercialization of each Licensed Product; (b) review and approve the Commercialization Plan and any amendments thereto as provided in Section 6.3; (c) review the periodic reports provided by Licensee pursuant to Section 6.7 and otherwise monitor Licensee's activities under and compliance with the Commercialization Plan; (d) review the Manufacture of Licensed Products as provided in Section 7.1.2(a); (e) monitor the conduct of, and establish the Post-Approval Budget for, any Post-Approval Commitments conducted by the Licensor as provided in Section 6.2; (f) be apprised of the conduct of Phase IIIB Clinical Studies, Phase IV Clinical Studies or Post-Approval Commitments conducted by the Licensee as provided in Section 6.2; (g) be apprised of any filings with the FDA relating to Product Labeling or the NDA and other filings with the FDA (other than submissions to DDMAC) in the Field in the Territory on or after the date of Regulatory Approval Transfer; (h) review and comment on submissions to the FDA relating to significant changes to the Product Labeling for safety or efficacy, (i) create such other committees with such responsibilities as the Parties may mutually agree to from time to time; and (j) perform such other functions as are set forth herein or as the Parties may mutually agree in writing, except where in conflict with any provision of this Agreement. In the event that Licensee elects to Develop any Licensed Product other than the Existing Licensed Product in the Field in the Territory or the Existing Licensed Product for an indication in the Field other than BPH in connection with life cycle management, the JCC shall form a subcommittee to review and approve a strategy throughout the Territory for such Development of and Regulatory Approvals for such Licensed Product in the Field in the Territory. The chairperson of the JCC shall be appointed by Licensee.
Sample 1
Joint Commercial Committee. 3.1 Members; Officers
Sample 1
Joint Commercial Committee 
Sample 1Sample 2Sample 3See All (6)

Related to Joint Commercial Committee

  • Joint Commercialization Committee As of the Effective Date, the Parties have established a joint commercialization committee (the “Joint Commercialization Committee” or the “JCC”), composed of up to [ * ] representatives of each Party, to monitor and discuss the Commercialization of Products at the operational level. Each JCC representative shall have knowledge and expertise in the commercialization of products similar to Products. The JCC shall in particular:

  • Development Committee As soon as practicable, the Parties will establish a joint development committee, comprised of at least one (1) and up to two (2) representatives of Omega and at least one (1) and up to two (2) representatives of Acuitas (the “JDC”). One such representative from each Party will be such Party’s Workplan Leader. Each Party may replace its Workplan Leader and other JDC representatives at any time upon written notice to the other Party, provided, however, that each Party shall use reasonable efforts to ensure continuity on the JDC. With the consent of the other Party (which will not be unreasonably withheld, conditioned or delayed), each Party may invite non-voting employees and consultants to attend JDC meetings as necessary, subject to consultant’s agreement to be bound to the same extent as a permitted subcontractor under Section 3.1(i).

  • Steering Committee Each Party shall name a mutually agreed upon equal number of representatives for the Steering Committee, which shall meet twice per calendar year, or as otherwise mutually agreed by the Parties. In the event that a Steering Committee dispute cannot be resolved, such dispute shall be escalated to a senior executive of each of Customer and Lonza. The primary function of the Steering Committee is to ensure the ongoing communication between the Parties and discuss and resolve any issues arising under this Agreement. In addition to the primary function described above, the Steering Committee shall also take on the following responsibilities:

  • Joint Development Committee The Parties shall form a joint development committee (the “Joint Development Committee” or “JDC”), made up of an equal number of representatives of Merck and BioLineRx, which shall have responsibility of coordinating all regulatory and other activities under, and pursuant to, this Agreement. Each Party shall designate a project manager (the “Project Manager”) who shall be responsible for implementing and coordinating activities, and facilitating the exchange of information between the Parties, with respect to the Study. Other JDC members will be agreed by both Parties. The JDC shall meet as soon as practicable after the Effective Date and then no less than twice yearly, and more often as reasonably considered necessary at the request of either Party, to provide an update on the progress of the Study. The JDC may meet in person or by means of teleconference, Internet conference, videoconference or other similar communications equipment. Prior to any such meeting, the BioLineRx Project Manager shall provide an update in writing to the Merck Project Manager, which update shall contain information about the overall progress of the Study, recruitment status, interim analysis (if results available), final analysis and other information relevant to the conduct of the Study. In addition to a Project Manager, each Party shall designate an alliance manager (the “Alliance Manager”), who shall endeavor to ensure clear and responsive communication between the Parties and the effective exchange of information, and shall serve as the primary point of contact for any issues arising under this Agreement. The Alliance Managers shall have the right to attend all JDC meetings and may bring to the attention of the JDC any matters or issues either of them reasonably believes should be discussed, and shall have such other responsibilities as the Parties may mutually agree in writing. In the event that an issue arises and the Alliance Managers cannot or do not, after good faith efforts, reach agreement on such issue, the issue shall be elevated to the Head of Clinical Oncology for Merck and the Vice President of Medical Affairs or Business Development for BioLineRx.

  • Joint Steering Committee [***] following the Effective Date [***], a joint steering committee (the “JSC”) will be established by the Parties to provide oversight and to facilitate information sharing between the Parties with respect to the activities under this Agreement.

  • Joint Manufacturing Committee A joint manufacturing committee (the “Joint Manufacturing Committee” or “JMC”) will be established pursuant to the Supply Agreement. The roles and responsibilities of the JMC shall be as specified in the Supply Agreement.

  • Operating Committee 7.01 To coordinate the operation of their respective generating, transmission and substation facilities, in order that the advantages to be derived hereunder may be realized by the parties hereto to the fullest practicable extent, the parties shall establish a committee of authorized representatives to be known as the Operating Committee. Each of the parties shall designate in writing delivered to the other party, the person who is to act as its representative on said committee (and the person or persons who may serve as alternates whenever such representative is unable to act). Each of such representatives and alternates shall be persons familiar with the generating, transmission, and substation facilities of the system of the party he represents, and each shall be fully authorized (1) to cooperate with the other representative (or alternates) and (2) to determine and agree from time to time, in accordance with this agreement and with any other relevant agreements then in effect between the parties, upon the following:

  • Advisory Committee (a) The Partnership shall have a committee (the “Advisory Committee”) consisting of Fund Investors or their representatives or designees selected by the Managing General Partner; provided that no member of the Advisory Committee shall be an Affiliate of the Managing General Partner (or a designee or representative thereof). The Managing General Partner will meet with the Advisory Committee at least semi-annually to consult on various matters concerning the Partnership, including financial statements and appraisals, the status of existing investments and such other matters as the Managing General Partner may determine or any member of the Advisory Committee may reasonably propose.

  • Joint Research Committee The Parties hereby establish a committee to facilitate the Research Program as follows:

  • Joint Patent Committee (a) The Parties will establish a “

Time is Money Join Law Insider Premium to draft better contracts faster.